Compugen Expands Clinical Collaboration Agreement with Bristol Myers Squibb with Phase 1b Combination Study of COM701 with Opdivo

Elana Holzman?
Director, Investor Relations and Corporate Communications Compugen Ltd.?
Email:?elanah@cgen.com?
Tel: +972 (3) 765-8124 Investor Relations contact:?
Bob Yedid?
LifeSci Advisors, LLC
Email:?bob@lifesciadvisors.com???
Tel: +1 (646) 597-6989 Media contact:
Josephine Belluardo, Ph.D.
LifeSci Communications?
Email:?jo@lifescicomms.com
Tel: +1 (646) 751-4361 SOURCE Compugen Ltd.
